Randomised Phase II Trial to Evaluate the Strategy of Integrating Local Ablative Therapy with First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer
This study aims to assess the clinical benefit of local ablative therapy (LAT) following initial standard first-line systemic treatment, compared to continued standard first-line systemic treatment in patients with unresectable oligometastatic CRC.
Primary Sponsor
Australasian Gastro-Intestinal Trials Group (AGITG)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG)
Accrual Target
50
Final Accrual
6
Expected Date of Accrual
31 December 2026
Closing Date of Accrual
31 December 2025
Trial Chairperson
Dr Julie Chu, Peter MacCallum Cancer Centre, VIC, Australia
Trial Contact
qa@trog.com.au
Related Post
20 May, 2026
TROG trials in the spotlight at ESTRO26 international conference
LATEST NEWS: 20 MAY A number of TROG trials
18 May, 2026
FASTRACK II trial finds emerging radiotherapy technique effectively controls kidney cancer
LATEST NEWS: 18 MAY 2026 A new non-invasive form